Abstract
CNS disease, or central neuropsychiatric lupus erythematosus (cNPSLE), occurs frequently in pediatric lupus, leading to significant morbidity and poor long-term outcomes. Diagnosing cNPSLE is especially difficult in pediatrics; many current diagnostic tools are invasive and/or costly, and there are no current accepted screening mechanisms. The most complicated aspect of diagnosis is differentiating primary disease from other etiologies; research to discover new biomarkers is attempting to address this dilemma. With many mechanisms involved in the pathogenesis of cNPSLE, biomarker profiles across several modalities (molecular, psychometric and neuroimaging) will need to be used. For the care of children with lupus, the challenge will be to develop biomarkers that are accessible by noninvasive measures and reliable in a pediatric population.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 545-558 |
| Number of pages | 14 |
| Journal | Biomarkers in Medicine |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2015 |
Fingerprint
Keywords
- biomarkers
- CNS
- neuropsychiatric
- pediatric
- systemic lupus erythematosus
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Drug Discovery
Cite this
Biomarkers for CNS involvement in pediatric lupus. / Rubinstein, Tamar; Putterman, Chaim; Goilav, Beatrice.
In: Biomarkers in Medicine, Vol. 9, No. 6, 01.06.2015, p. 545-558.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biomarkers for CNS involvement in pediatric lupus
AU - Rubinstein, Tamar
AU - Putterman, Chaim
AU - Goilav, Beatrice
PY - 2015/6/1
Y1 - 2015/6/1
N2 - CNS disease, or central neuropsychiatric lupus erythematosus (cNPSLE), occurs frequently in pediatric lupus, leading to significant morbidity and poor long-term outcomes. Diagnosing cNPSLE is especially difficult in pediatrics; many current diagnostic tools are invasive and/or costly, and there are no current accepted screening mechanisms. The most complicated aspect of diagnosis is differentiating primary disease from other etiologies; research to discover new biomarkers is attempting to address this dilemma. With many mechanisms involved in the pathogenesis of cNPSLE, biomarker profiles across several modalities (molecular, psychometric and neuroimaging) will need to be used. For the care of children with lupus, the challenge will be to develop biomarkers that are accessible by noninvasive measures and reliable in a pediatric population.
AB - CNS disease, or central neuropsychiatric lupus erythematosus (cNPSLE), occurs frequently in pediatric lupus, leading to significant morbidity and poor long-term outcomes. Diagnosing cNPSLE is especially difficult in pediatrics; many current diagnostic tools are invasive and/or costly, and there are no current accepted screening mechanisms. The most complicated aspect of diagnosis is differentiating primary disease from other etiologies; research to discover new biomarkers is attempting to address this dilemma. With many mechanisms involved in the pathogenesis of cNPSLE, biomarker profiles across several modalities (molecular, psychometric and neuroimaging) will need to be used. For the care of children with lupus, the challenge will be to develop biomarkers that are accessible by noninvasive measures and reliable in a pediatric population.
KW - biomarkers
KW - CNS
KW - neuropsychiatric
KW - pediatric
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=84931307705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931307705&partnerID=8YFLogxK
U2 - 10.2217/bmm.15.26
DO - 10.2217/bmm.15.26
M3 - Article
VL - 9
SP - 545
EP - 558
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
SN - 1752-0363
IS - 6
ER -